ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Iron

Also written as “PA21”, “PA21 (2.5 g tablet containing 500 mg iron)” and “CTX001 With Iron”.

Its studies are mostly in Hyperphosphatemia · Anemia · Renal Insufficiency, Chronic · Colorectal Neoplasms, led by 4 companies.

Drug pageIron: every studyAll 86 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Mar 24, 201117 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSLits history only100 open or runningphase 3since Mar 24, 2011Jan 9, 2009none ahead
Kissei Pharmaceutical50 open or runningphase 3since Apr 12, 2013Jan 26, 2012none ahead
Cajal Therapeuticsits history only11 open or runningearly phase 1since May 5, 2026May 5, 2026none ahead
J. Uriachits history only10 open or runningphase 4since Sep 16, 2005Sep 16, 2005none ahead

Also a collaborator on its studies: Fresenius Medical Care.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Kissei Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 26, 2012First study: phase 2 study in HyperphosphatemiaFirst studyNCT01521494 · 183 enrolled · Japan
  2. Apr 12, 2013Phase 3 study in HyperphosphatemiaNCT01833494 · 161 enrolled · Japan
  3. May 7, 20133 phase 3 studies in HyperphosphatemiaNCT01852682, NCT01850641, NCT01850602

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 Kissei Pharmaceutical leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01852682Hyperphosphatemia · Japan3CompletedMar 2014
NCT01850641Hyperphosphatemia · Japan3CompletedDec 201335
NCT01850602Hyperphosphatemia · Japan3CompletedDec 2013213
NCT01833494Hyperphosphatemia · Japan3CompletedAug 2014161
NCT01521494Hyperphosphatemia · Japan2CompletedJul 3, 2012183

How it is read

Names in the registry

  • “PA21”, 11 entries
  • “PA21 (2.5 g tablet containing 500 mg iron)”, 2 entries
  • “CTX001 With Iron”, 1 entry
  • “IV iron”, 1 entry
  • “1.25 g PA21 (250 mg iron)”, 1 entry

Codes read as this program: PA21.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.